Vaccination Prior To COVID-19 Infection Provided 60% Protection Against Post-Discharge Mortality: ICMR Research Study

New Delhi : The study on factors related to the post-discharge one-year mortality among hospitalized COVID-19 patients study conducted by the Indian Council of Medical Research (ICMR) has revealed that vaccination prior to the COVID-19 infection (at least a single dose) provided 60 percent protection against post-discharge mortality. The study read,

“The study found a higher chance of dying within one year after discharge in males, those more than 40 years of age, those with comorbidities and those who had moderate-severe COVID disease to begin with. Vaccination prior to the COVID-19 infection (at least a single dose) provided 60% protection against post-discharge mortality. Similar trends were seen in participants, 18-45 years of age.”

It is worth mentioning that these results relate to patients who had been hospitalized during their initial COVID-19 infection and cannot be generalized to all COVID-19 patients.

The study conducted by the National Clinical Registry for Covid-19 team has evaluated the factors related to one-year post-discharge mortality. It said,

“National Clinical Registry for COVID-19 study team has conducted nested matched case-control analyses to evaluate the factors related to one-year post-discharge mortality.”

ICMR has been maintaining the National Clinical Registry for COVID-19 at 31 centres across the country, where all hospitalized COVID-19 patients were periodically contacted by telephone till one year after discharge. Data collected till February 2023 were included in this analysis.

According to the study,

“It was observed that of the 14,419 participants contacted at least once in one year after discharge from hospital, 942 (6.5%) all-cause mortality was reported. A nested matched case-control analysis was conducted to evaluate the factors related to one-year post-discharge mortality.”

ICMR is conducting more such studies like the Effect of the COVID-19 vaccine on thrombotic (blood clot within the blood vessels restricting the flow of blood) events among the 18–45-year-old population in India, 2022, said the Multicentric hospital-based matched case-control study.

Related Posts

Price cap on 2 key cancer drugs increased by 50%

NEW DELHI: Amid concerns over shortages of two critical cancer medicines, National Pharmaceutical Pricing Authority has approved a 50% hike in ceiling prices of Carboplatin and Cisplatin injections, citing escalating…

Hospitals can’t force patients to buy medicines from their pharmacies: Maha FDA

Mumbai: Food and Drug Administration (FDA) commissioner Tukaram Mundhe on Friday issued a directive to hospitals and nursing homes across the state to not make it binding on patients and their…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Price cap on 2 key cancer drugs increased by 50%

Price cap on 2 key cancer drugs increased by 50%

Hospitals can’t force patients to buy medicines from their pharmacies: Maha FDA

Hospitals can’t force patients to buy medicines from their pharmacies: Maha FDA

IIT Bhubaneswar researchers develop portable device for accurate arsenic detection

IIT Bhubaneswar researchers develop portable device for accurate arsenic detection

Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case

No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case

Crackdown on Illegal Sale of Mephentermine Sulphate Injections in Warangal Gyms

Crackdown on Illegal Sale of Mephentermine Sulphate Injections in Warangal Gyms